Your browser doesn't support javascript.
Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment.
Vellas, Camille; Kamar, Nassim; Izopet, Jacques.
  • Vellas C; INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse F-31300, France; Toulouse University Hospital, Virology Laboratory, Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31300, France. Electronic address: camille.vellas@inserm.fr.
  • Kamar N; INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31300, France; Toulouse University Hospital, Department of Nephrology, Dialysis, and Multi-Organ Transplantation, Toulouse, F-31300 France.
  • Izopet J; INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse F-31300, France; Toulouse University Hospital, Virology Laboratory, Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31300, France. Electronic address: izopet.j@chu-toulouse.fr.
J Infect ; 85(5): e162-e163, 2022 11.
Article in English | MEDLINE | ID: covidwho-1956228
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Topics: Variants Limits: Humans Language: English Journal: J Infect Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Topics: Variants Limits: Humans Language: English Journal: J Infect Year: 2022 Document Type: Article